{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","pValueComment":"Two-sided test","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.5","upperLimit":"22.2","value":"20.7"},{"groupId":"OG001","lowerLimit":"8.8","upperLimit":"10.9","value":"10.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"676"},{"groupId":"OG001","value":"444"}],"units":"Participants"}],"description":"Overall survival time is defined as time from registration to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. Progression is defined as greater than 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period.","dispersionType":"95% Confidence Interval","groups":[{"id":"OG000","title":"No Progression at 6 Months"},{"id":"OG001","title":"Progression at 6 Months"}],"paramType":"MEDIAN","populationDescription":"Per the protocol, both arms are combined to compare between 6-month progression status. Eligible pre-randomization participants with any follow-up data.","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.","title":"Overall Survival Status by Progression Status at 6 Months","type":"SECONDARY","unitOfMeasure":"months"}